←Back to Expert Scholars
Translational Medicine / 转化医学Biliary Tract Cancer Combination Therapy
Andrew X. Zhu
MD, PhD
🏢Jiahui Health and Massachusetts General Hospital🌐USA
Director, Jiahui International Cancer Center
85
h-index
0
Key Papers
0
Key Contributions
👥Biography 个人简介
Dr. Andrew Zhu is a leader in hepatobiliary medical oncology with extensive contributions to hepatocellular and cholangiocarcinoma drug development. He led the pivotal pemigatinib trial in FGFR2 fusion cholangiocarcinoma. His career spans pivotal trials across hepatobiliary malignancies.
Share:
🧪Research Fields 研究领域
hepatocellular carcinoma
biliary tract cancer
pemigatinib
clinical trials
targeted therapy
🎓Key Contributions 主要贡献
Representative Works 代表性著作
📄Data Sources 数据来源
Last updated: 2026-04-01 | All information from publicly available academic sources
Related Experts 相关专家
Antoni Ribas
UCLA Jonsson Comprehensive Cancer Center
Melanoma ImmunotherapyCheckpoint Inhibitors
Drew M. Pardoll
Johns Hopkins University
Cancer ImmunologyPD-1/PD-L1 Pathway
Padmanee Sharma
MD Anderson Cancer Center
Bladder Cancer ImmunotherapyImmune Profiling
Naiyer A. Rizvi
Columbia University Irving Medical Center
Lung Cancer ImmunotherapyTumor Mutational Burden
关注 Andrew X. Zhu 的研究动态
Follow Andrew X. Zhu's research updates
留下邮箱，当我们发布与 Andrew X. Zhu（Jiahui Health and Massachusetts General Hospital）相关的新研究或访谈时，我们会通知你。
Explore More Experts
Discover the researchers shaping the future of cancer treatment